logo remtec selection
 
  homeclientscandidatesMedical DeviceLife Sciencesnewsabout uscontact us  
 

News

 
   
     

Remtec News

Messing about on the water - Remtec Go Punting

Messing about on the water - Remtec Go Punting

Summer’s here and the Remtec team have been out team building and bonding, enjoying that most traditional of Cambridge pursuits the team spent the afternoon on the river punting.

Find out more...


Ian Sandison - A Working Day

Ian Sandison - A Working Day

Commerical Director of Remtec Search and Selection Ltd, Ian Sandison describes his working day...

Find out more...


Remtec training academy drives growth plans

Remtec training academy drives growth plans

A new innovative professional training academy will offer the chance of a successful career in recruitment to those who complete the course!

Find out more...


Strategic Alliance aimed at business growth

Strategic Alliance aimed at business growth

A new strategic alliance between two Cambridge based companies will provide a comprehensive recruitment solution to the healthcare marketplace.

Find out more...


The Remtec runners raised £1500 for the Remtec Grassroots Community Fund

The Remtec runners raised £1500 for the Remtec Grassroots Community Fund

The weeks of training paid off and the whole of the Remtec team completed the Sawston Fun Run in very respectable times.

Find out more...


The ERBI Conference - 2nd & 3rd June 2010

The ERBI Conference - 2nd & 3rd June 2010

Remtec will be attending Europe's largest Life Science and Healthcare gathering, The ERBI Conference.

Find out more...


Please sponsor our team who are taking part in the Sawston Fun Run on the 9th May 2010

Please sponsor our team who are taking part in the Sawston Fun Run on the 9th May 2010

The team at Remtec Search and Selection are running the Sawston fun run on the 9th May 2010 to raise money for the Remtec Grassroots community fund which raises money for local charties across the Cambridgeshire region.

Sponsor us here: http://www.localgiving.com/remtec

Find out more...


Retained Search: It doesn’t need to take so long! - March 2010

Retained Search: It doesn’t need to take so long! - March 2010

Remtec completes another senior retained search assignment in less than eight weeks

Find out more...


We want your old Mobile Phones!

We want your old Mobile Phones!

Remtec is aiming to raise £15k for the Cambridgeshire Community Foundation

Find out more...


ERBI NETWORK MEETING - Demystifying the Regulatory Process for Drugs and Devices

ERBI NETWORK MEETING - Demystifying the Regulatory Process for Drugs and Devices

Remtec Search and Selection are sponsoring the next ERBI event on Thursday 28th January 2010 - 'Demystifying the Regulatory Process for Drugs and Devices' .

Find out more...


Remtec will be attending Genesis 2009

Remtec will be attending Genesis 2009

Ian Sandison will be representing Remtec at the forth coming Genesis conference on Thursday 10th December.

Find out more...


Remtec sets up a new charitable fund with Cambridgeshire Community Foundation

Remtec sets up a new charitable fund with Cambridgeshire Community Foundation

Remtec are pleased to announce the new charitable fund they have set up with the Cambridge Community Foundation.

Find out more...


Remtec will be attending Medica 2009 in Dusseldorf - 18th - 21st November

Remtec will be attending Medica 2009 in Dusseldorf - 18th - 21st November

The world’s largest medical trade fair, the MEDICA, covers the entire spectrum of exhibits for both ambulant and in-patient treatment.

Over 4,300 exhibitors – from small innovative companies to global players – will be presenting services and established products on almost 120,000 m2 in 17 exhibition halls.

Find out more...


Remtec will be attending Bench2Boardroom 2009 - 21 October

Remtec will be attending Bench2Boardroom 2009 - 21 October

B2B is the UK's largest Biotech and Medtech networking exhibition. It is an intensive one day event, covering a wide range of topics and attracting well over 500 individuals from 14 countries.

Find out more...


Remtec will be attending IBMS Biomedical Congress 2009

Remtec will be attending IBMS Biomedical Congress 2009

Remtec will be represented by Clare Willmott at the forthcoming IBMS Biomedical Conference. - http://www.ibmscongress.com/

Find out more...


"Now you've raised the cash, how do you find the people you need to build your company?"

There has been plenty written on the subject of how to raise finance to fund a new business venture but what do you do once you have the money in the bank?  How do you find the people you need to grow your company?

Find out more...


Clare Willmott joins the Remtec Search and Selection team - July 2009

Clare Willmott joins the Remtec Search and Selection team - July 2009

Remtec is pleased to welcome Clare Willmott who joins as a Recruitment Consultant and brings a wealth of experience to the team.

Find out more...


Remtec welcomes Jonathan Deacon to the Research Team

Remtec welcomes Jonathan Deacon to the Research Team

Jonathan joined Remtec earlier this year to support their already established retained search team.

Find out more...


The tomorrow salespeople

The tomorrow salespeople

What skills will you need to sell or market healthcare technologies in the next decade? Ian Sandison of Remtec Search and Selection takes a look at what the future holds for medical device sales.

Find out more...


Redundancy: nightmare or opportunity?

Redundancy: nightmare or opportunity?

Have you ever dreamt of an HR manager handing you a P45, and woken up afraid to look behind you in case you saw your career? Ian Sandison of Remtec explains why redundancy is not always to be feared.

Find out more...

Industry News

Novartis drug Tasigna® approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML - 27/08/10

Novartis drug Tasigna® approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML - 27/08/10

Pivotal Phase III trial data demonstrate superiority to standard of care Glivec® in achieving molecular and cytogenetic response, delaying cancer progression at 12 months
Tasigna also available in United States in this indication; submissions under review worldwide
Basel, August 27, 2010 - The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since the introduction of Glivec® (imatinib)*, providing a major advance for patients with this blood cancer.
 

Find out more...


Merck Provides New Funding to Fight HIV/AIDS in Botswana- 24/08/10

Merck Provides New Funding to Fight HIV/AIDS in Botswana- 24/08/10

Merck Company Foundation Supports Successful HIV/AIDS Initiative Led by Government

Find out more...


CE Mark Approval of New Five-Lumen Spectrum Catheter Reduces Risk of Deadly Infections in European Patients- 23/08/10

CE Mark Approval of New Five-Lumen Spectrum Catheter Reduces Risk of Deadly Infections in European Patients- 23/08/10

Limerick, Ireland, August 23, 2010 — With the addition of the new five-lumen central venous catheter (CVC), Cook Medical now provides a full line of Spectrum® technology products for physicians and patients in Europe. The five-lumen CVC was created in response to physician demand and provides ease and convenience to health-care centers, providing Spectrum multi-lumen catheter technology needed in the most demanding critical care cases.

Find out more...


Baxter Announces Manufacturing, Supply and Distribution Agreement with Kamada for GLASSIATM- 24/08/10

Baxter Announces Manufacturing, Supply and Distribution Agreement with Kamada for GLASSIATM- 24/08/10

Baxter Acquires Exclusive Commercial Rights to GLASSIATM in the United States and Other Select Markets

Find out more...


New Optical Imaging Technique to Improve Angioplasty - 18.08.10

A new optical imaging technique combining optical coherence tomography with a balloon deployment system can improve angioplasty procedures, according to a study published in Review of Scientific Instruments.
 

Find out more...


Automated Cell Biology Workflows With Tecan And Miltenyi Biotec - 18.08.10

Automated Cell Biology Workflows With Tecan And Miltenyi Biotec - 18.08.10

Tecan is working with Miltenyi Biotec, a leading provider of cell biology solutions, to develop a range of automated solutions for cell biology, based on the powerful MACS(R) Magnetic bead technology.

Find out more...


Zimmer Announces First Implantation Of NCB(R) Periprosthetic Plating System - 14.08.10

Zimmer Announces First Implantation Of NCB(R) Periprosthetic Plating System - 14.08.10

Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal care, announced the first implantation of the Zimmer(R) NCB (Non-Contact Bridging) Periprosthetic Plating System. Scheduled for full release in the Fall of 2010, the Zimmer NCB Periprosthetic Plating System is the first comprehensive solution available to address complex femoral fractures which can occur around a hip or knee implant.

Find out more...


New Defibrillator May Offer 24/7 Surveillance Without Touching The Heart 14.08.10

It's a familiar scene on most TV medical dramas: a patient is unconscious; CPR didn't work; someone yells, "All clear!" and the defibrillator paddles are applied to the person's chest in hopes the electric current shocks the heart back into action.

Find out more...


Boston Scientific Resolves Corporate Warning Letter - 11.08.10

Boston Scientific Resolves Corporate Warning Letter - 11.08.10

NATICK, Mass., Aug. 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has been notified by the U.S. Food and Drug Administration that all issues cited in the Company's corporate warning letter have been resolved. 

Find out more...


Teleflex Medical OEM Announces New Website for Specialized Medical Devices - 10.08.10

Teleflex Medical OEM Announces New Website for Specialized Medical Devices - 10.08.10

Product development professionals interested in precision-machined instruments, implants and components have an outstanding new resource thanks to a redesign and upgrade of the Specialized Medical Devices (SMD™) website by Teleflex Medical OEM.

Find out more...


Merck Partners With Sesame Workshop on National Program to Encourage Healthy Eating Habits in Families with a Limited Budget - 10.08.10

Merck Partners With Sesame Workshop on National Program to Encourage Healthy Eating Habits in Families with a Limited Budget - 10.08.10

WHITEHOUSE STATION, N.J., Aug 10, 2010 – Merck, a global healthcare leader working to help the world to be well, and Sesame Workshop, the nonprofit educational organization behind Sesame Street, are partnering to develop Food for Thought: Eating Well on a Budget, a bilingual education outreach program aimed at helping low-income families make food choices that are affordable, nutritional and set the foundation for lifelong healthy habits.

Find out more...


Merck’s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection - 04.08.10

Merck’s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection - 04.08.10

In Pivotal Phase III Studies, Merck’s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection Achieve Sustained Virologic Response, the Primary Endpoint of the Studies Merck Expects to Submit NDA by Year-End

Find out more...


BD Receives CLIA "Moderate Complexity" Status for the BD MAX™ GBS Assay - 03.08.10

BD Receives CLIA

Find out more...


Boston Scientific Begins Clinical Trial Enrollment for New Coronary Stent with Bioabsorbable Polymer and Everolimus Drug Coating - 03.08.10

Boston Scientific Begins Clinical Trial Enrollment for New Coronary Stent with Bioabsorbable Polymer and Everolimus Drug Coating - 03.08.10

EVOLVE trial to evaluate Company's fourth-generation SYNERGY™ drug-eluting coronary stent

Find out more...


AGA Medical Reports 2010 Second Quarter Financial Results - 03.08.10

AGA Medical Reports 2010 Second Quarter Financial Results - 03.08.10

Second Quarter Net Sales $53.8 Million; Gross Margin at 85.5%

Find out more...


Bill Cook receives Pioneer Award from Pediatric and Adult Interventional Cardiac Symposium - 02.08.10

Bill Cook receives Pioneer Award from Pediatric and Adult Interventional Cardiac Symposium - 02.08.10

Cook Medical is proud to announce that its founder, Bill Cook, recently received the Pioneer Award from the Pediatric and Adult Interventional Cardiology Symposium (PICS-AICS).

Find out more...


Gilead Closes Sale of $2.2 Billion of Convertible Senior Notes - 30.07.10

Gilead Closes Sale of $2.2 Billion of Convertible Senior Notes - 30.07.10

Find out more...


AstraZeneca PLC Appoints New Non-Executive Director - 29.07.10

AstraZeneca PLC Appoints New Non-Executive Director - 29.07.10

AstraZeneca today announced that Dr Bruce Burlington is to join the Board of Directors as a Non-Executive Director, with effect from 1 August 2010.  Dr Burlington will also become a member of the Board’s Science Committee.

Find out more...


SORIN GROUP DELIVERS SOLID RESULTS FOR THE FIRST HALF OF 2010 AND IMPROVES THE GUIDANCE FOR THE FULL YEAR - 29.07.10

SORIN GROUP DELIVERS SOLID RESULTS FOR THE FIRST HALF OF 2010 AND IMPROVES THE GUIDANCE FOR THE FULL YEAR - 29.07.10

Results of the Second Quarter 2010:

•    Consolidated revenues at €197.5 million, up 8.8% (5.1%°*) compared with the second quarter of 2009;•    Gross profit at €117.3 million, or 59.4% of revenues (54.4% in the second quarter of  2009);•    EBITDA at € 31.9 million, or 16.2% of revenues (14.3% in the second quarter of 2009)

Find out more...


Abbott's Enhanced ARCHITECTPLUS Systems Helps Labs Manage Surging Testing Demand Due to Aging Population - 27.07.10

Abbott's Enhanced ARCHITECTPLUS Systems Helps Labs Manage Surging Testing Demand Due to Aging Population - 27.07.10

Anaheim, California — As hospital and clinical laboratories endure increasingly intense pressures to do more with less, they now face another challenge — rising demand for medical tests driven by an aging U.S. population that is expected to swell to more than 70 million in the next 20 years, an increase of more than 80 percent from today.

Find out more...


Sanofi-aventis and Merck Appoint Raul Kohan as CEO for the New Animal Health Joint Venture - 27.07.10

Sanofi-aventis and Merck Appoint Raul Kohan as CEO for the New Animal Health Joint Venture - 27.07.10

Proposed JV to be called Merial-Intervet

Find out more...


Gilead Prices $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock - 27.07.10

Gilead Prices $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock - 27.07.10

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the pricing of its offering of $1.1 billion aggregate principal amount of 1.00% convertible senior notes due 2014 and $1.1 billion aggregate principal amount of 1.625% convertible senior notes due 2016 to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

Find out more...


BD Board of Directors Elects Christopher Jones - 26.07.10

BD Board of Directors Elects Christopher Jones - 26.07.10

Franklin Lakes, N.J. (July 26, 2010) -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it has elected Christopher Jones to its Board of Directors, effective today.

Find out more...


Boston Scientific Launches Neuroform EZ™ Stent System in U.S. and Europe - 26.07.10

Boston Scientific Launches Neuroform EZ™ Stent System in U.S. and Europe - 26.07.10

Company expands market-leading family of neurovascular stents

Find out more...


Codman Launches Softest Endovascular Finishing Coil - 26.07.10

Codman Launches Softest Endovascular Finishing Coil - 26.07.10

New XTRASOFT™ ORBIT GALAXY™ Coil with TRUSEEK™ Technology
Designed to Seek and Fill Open Spaces in Cerebral Aneurysms

Find out more...


Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox® - 23.07.10

Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox® - 23.07.10
  • Sandoz is the first company to receive US approval to market a more affordable generic version of the leading hospital-based medication in the US
  • US 2009 sales of Lovenox® were USD 2.7 billion
  • Enoxaparin launch demonstrates Sandoz focus on differentiated and complex products, and underscores status as a global leader

Find out more...


AGA Medical to Host Second Quarter Earnings Conference Call on Tuesday, Aug. 3, 2010 - 22.07.10

AGA Medical to Host Second Quarter Earnings Conference Call on Tuesday, Aug. 3, 2010 - 22.07.10

AGA Medical Holdings, Inc. (AGA Medical) (Nasdaq: AGAM) will hold a live webcast to discuss its second quarter operating results on Tuesday, Aug. 3, 2010 at 8 a.m. ET (7 a.m. CT).

Find out more...


Multiple Studies Show that Cook Medical BIGopsy Backloading Biopsy Forceps Can Aid in Proper Cancer Diagnosis - 20.07.10

Multiple Studies Show that Cook Medical BIGopsy Backloading Biopsy Forceps Can Aid in Proper Cancer Diagnosis - 20.07.10

San Francisco, CA – July 20, 2010 — Two independent clinical studies show that Cook Medical's BIGopsy® Backloading Biopsy Forceps' ability to obtain larger tissue samples for biopsy can lead to an improved ability to diagnose the cause of suspicious ureteral or kidney lesions. The results of both studies were presented separately at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco.

Find out more...


Roche launches new immunoassay module for large volume laboratories - 20.07.10

Roche launches new immunoassay module for large volume laboratories - 20.07.10

New cobas e 602 module allows customers to integrate immunoassay and clinical chemistry testing on a single platform

Find out more...


DR. SCHOLL'S® Custom Fit™ Orthotic Inserts Now Available in Stores Nationwide - 13/07/10

DR. SCHOLL'S® Custom Fit™ Orthotic Inserts Now Available in Stores Nationwide - 13/07/10

Merck Consumer Care, a subsidiary of Merck & Co., Inc., announces the nationwide availability of Dr. Scholl’s® Custom Fit Orthotic Centers. To help people find customized solutions for their tired, achy feet, the kiosks use revolutionary FootMapping® Technology to measure arch type and the areas you put the most pressure on to recommend the most appropriate Custom Fit™ Orthotic.

Find out more...


Real-World Experience Confirms Low Inhibitor Rate Established in ADVATE Controlled Clinical Studies for Hemophilia Patients- 13/07/10

Real-World Experience Confirms Low Inhibitor Rate Established in ADVATE Controlled Clinical Studies for Hemophilia Patients- 13/07/10

Japan PASS interim results presented at Hemophilia 2010 World Congress

Find out more...


Biomet - Have you seen our new advert? - 13.07.10

Biomet - Have you seen our new advert?  - 13.07.10

Launching in the July edition of JBJS, our new technologies advertising campaign kicks off with E1™.  The theme of the campaign is ‘no magic, just technology’.

Find out more...


AccuVein AV300 Praised as “Revolutionary Device” in News Santé (Europe) - 12.07.10

AccuVein AV300 Praised as “Revolutionary Device” in News Santé (Europe) - 12.07.10

July 12, 2010   News Santé (Europe) – Dr. Erard de Hemricourt – Nuclear Medicine, Dunkirk, France

Find out more...


Johnson & Johnson Announces Definitive Agreement - 12.07.10

Johnson & Johnson Announces Definitive Agreement - 12.07.10

Combination of Neurovascular Businesses to Advance the Treatment of Stroke

Find out more...


A New Study Shows that Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test- 08/07/10

A New Study Shows that Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test- 08/07/10

1 in 10 women in the ATHENA trial, age 30-years and older, who tested positive for HPV genotypes 16 and/or 18 by the cobas 4800 HPV Test had cervical pre-cancer, although their Pap test was normal
Involving more than 47,000 women, the ATHENA trial is the largest registration study ever conducted for cervical cancer screening

Find out more...


Merck Details Plans to Advance Integration of R&D, Manufacturing and Business Operations Worldwide - 08/07/10

Merck Details Plans to Advance Integration of R&D, Manufacturing and Business Operations Worldwide - 08/07/10

Merck & Co., Inc. (NYSE: MRK), known outside the U.S. and Canada as MSD, today provided further detail on integration plans for the company's research and development, manufacturing and other business operations as part of a global restructuring program announced following the November 2009 merger of Merck and Schering-Plough. The consolidation plans support Merck's strategic direction as a customer focused, innovative and diversified global health care company, and position the company to invest in key areas for future growth, including emerging markets, biologics, vaccines and consumer care.

Find out more...


Boston Scientific Announces First Patient Enrollment in MultiSENSE Clinical Trial- 08/07/10

Boston Scientific Announces First Patient Enrollment in MultiSENSE Clinical Trial- 08/07/10

Boston Scientific Corporation (NYSE: BSX) today announced enrollment of the first patient in its MultiSENSE clinical trial. The trial is designed to evaluate multiple physiologic sensors in the Company's COGNIS™ cardiac resynchronization therapy defibrillators (CRT-Ds).  Boston Scientific plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure.  The first patient was enrolled by Paul Coffeen, M.D., Austin Heart, Austin, Texas, where Jeffrey Whitehill, M.D., Medical Chair, Electrophysiology Department, is the site's Principal Investigator.

Find out more...


BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call - 07/07/10

BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call - 07/07/10

BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2010 earnings conference call on Thursday, July 29, 2010 at 10:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning.

Find out more...


St. Jude Medical Completes Acquisition of LightLab Imaging - 06/07/10

St. Jude Medical Completes Acquisition of LightLab Imaging - 06/07/10

Acquisition makes St. Jude Medical the first company to offer both OCT and FFR technology
 

Find out more...


AstraZeneca and MRC Technology Form Strategic Alliance in Discovery Research, Utilising Shared Compound Libraries- 05/07/10

AstraZeneca and MRC Technology Form Strategic Alliance in Discovery Research, Utilising Shared Compound Libraries- 05/07/10

AstraZeneca and MRC Technology, the commercialisation company for the UK’s Medical Research Council, today announced a new strategic collaboration to share access to their collections of compounds to aid the search for potential new treatments for serious diseases.

Find out more...


Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patients- 01/07/10

Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patients- 01/07/10

 

  • Everolimus extended median progression-free survival from 4.6 to 11.0 months vs. placebo and reduced risk of cancer progression by 65%[1]

 

  • Patients with advanced pancreatic neuroendocrine tumors (NET) have a rare and aggressive form of cancer with limited treatment options[2,3]

 

  • Worldwide regulatory filings planned for everolimus as first mTOR inhibitor treatment for patients with advanced pancreatic NET

Find out more...


Patient Comfort a Key Benefit of Vein Visualization- 29/06/10

Patient Comfort a Key Benefit of Vein Visualization- 29/06/10

Over 275 Hospitals Now Using the AccuVein AV300 Vein Finder

Find out more...


MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program - 28.06.10

MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program - 28.06.10

MorphoSys Strengthens Clinical Portfolio with Innovative Antibody in Phase 1 Cancer Trial

Find out more...


Eden Research Announces Option Agreement with Certis Europe BV for Nematodes - 28.06.10

Eden Research Announces Option Agreement with Certis Europe BV for Nematodes - 28.06.10

Eden Research plc, a leading UK agrochemical development company, today announces that it has signed an exclusive option agreement for its nematicide product and technology with Certis Europe BV ("Certis") based in Maarssen, Netherlands.

Find out more...


The T-SPOT®.TB Test Now Included in New CDC Guidelines1 - 25.06.10

The T-SPOT®.TB Test Now Included in New CDC Guidelines1  - 25.06.10

TB Blood Tests Preferred for Targeted Groups

Find out more...


Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million - 25/06/10

Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million - 25/06/10

Gilead Sciences, Inc. (Nasdaq:GILD) and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI.

Find out more...


Abbott Receives FDA Clearance for New, Easier-to-Use FreeStyle® Test Strips-24/06/10

Abbott Receives FDA Clearance for New, Easier-to-Use FreeStyle® Test Strips-24/06/10
  •  New FreeStyle test strips do not use the GDH-PQQ enzyme.
  • New FreeStyle test strips are compatible with all FreeStyle blood glucose monitors and offer a better blood glucose testing experience.

Find out more...


Boston Scientific Announces FDA Approval and Launch of Lead Splitters for the Precision Plus™ Spinal Cord Stimulator System-24/06/10

Boston Scientific Announces FDA Approval and Launch of Lead Splitters for the Precision Plus™ Spinal Cord Stimulator System-24/06/10

Two new splitters allow multi-site placement of up to four spinal cord stimulation leads

Find out more...


St. Jude Medical Announces Japanese Approval of the Therapy Cool Path Ablation Catheter - 24/06/10

St. Jude Medical Announces Japanese Approval of the Therapy Cool Path Ablation Catheter - 24/06/10

The Therapy Cool Path is the company's first irrigated ablation catheter in Japan

Find out more...


Endovascular Fusion: The First Multidisciplinary Meeting of its Kind – Uniting Expertise in Vascular Surgery and Radiology- 22/06/10

Endovascular Fusion: The First Multidisciplinary Meeting of its Kind – Uniting Expertise in Vascular Surgery and Radiology- 22/06/10

The British Society of Endovascular Therapy (BSET), the British Society of Interventional Radiology (BSIR) and the Vascular Society of Great Britain and Ireland will unite at Endovascular Fusion on the 1st and 2nd of July, in the first meeting of its kind to discuss the latest advances in endovascular therapy. Six, six-month fellowships in aid of the advancement of endovascular surgery will be announced at this meeting.

Find out more...


BD and PEPFAR Collaboration Initiates Program to Improve Blood-Drawing Practices in Clinics and Hospitals in Sub-Saharan Africa - 21/06/10

BD and PEPFAR Collaboration Initiates Program to Improve Blood-Drawing Practices in Clinics and Hospitals in Sub-Saharan Africa  - 21/06/10

Government of Kenya Takes Leading Role in Launch of Multi-Year, In-Service Training Program

Find out more...


New hope for children with systemic Juvenile Idiopathic Arthritis- 18/06/10

New hope for children with systemic Juvenile Idiopathic Arthritis- 18/06/10

First presentation of TENDER study demonstrates RoACTEMRA’s strong efficacy in this severe childhood condition with no currently licensed treatment
 

Find out more...


New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy- 18/06/10

New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy- 18/06/10
  • ACZ885 significantly reduced rate of acute flares up to 75% vs. anti-inflammatory colchicine in gout patients starting uric acid lowering therapy (UALT)[1]
  • ACZ885 blocked major inflammation trigger (interleukin IL-1β)[2,3] for sustained period and reduced gout symptoms [4]
  • Data indicate potential of ACZ885 to both treat and prevent painful gout flares - Phase III program in gout currently underway

Find out more...


Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis- 16/06/10

Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis- 16/06/10

Abbott Park, Illinois (NYSE: ABT) and San Diego, California — Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

Find out more...


Baxter Opens New Research & Development Facility in Alliance Park - 17/06/10

Baxter Opens New Research & Development Facility in Alliance Park - 17/06/10

Belgium Facility Provides 15,500 Square Metre Office and Laboratory Space

Find out more...


Sorin Group (Reeuters Codde: SORIN .MI), a gloobal leaderr in the treaatment of cardiovasccular diseaases, annoounced todday that the CLEAR study hass met its priimary endppoint- 17/06/10

Sorin Group (Reeuters Codde: SORIN .MI), a gloobal leaderr in the treaatment of cardiovasccular diseaases, annoounced todday that the CLEAR study hass met its priimary endppoint- 17/06/10

Sorin Group’s exclusive SonR sensor technology improves responder rates for heart failure patients through the regular automatic optimization of CRT.

Find out more...


St. Jude Medical Announces European Approval of EnSite Contact Technology Platform- 17/06/10

St. Jude Medical Announces European Approval of EnSite Contact Technology Platform- 17/06/10

New technology designed to offer physicians objective, real-time measurements to better determine catheter tip-to-tissue contact during ablation procedures

Find out more...


CryoLife to Present at Sidoti's 2010 Semi Annual New York Micro-Cap Conference - 16/06/10

CryoLife to Present at Sidoti's 2010 Semi Annual New York Micro-Cap Conference - 16/06/10

CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the Sidoti & Company, LLC 2010 Semi Annual New York Micro-Cap Conference at The Grand Hyatt Hotel.

Find out more...


BD Biosciences to Fund $100,000 in Stem Cell Research Grants - 16/06/10

BD Biosciences to Fund $100,000 in Stem Cell Research Grants  - 16/06/10

New Stem Cell Grants Bring Research Grant Program Total to $240,000, Offering Additional Support for Innovative Life Sciences Research
 

Find out more...


Edwards Lifesciences to Present at the Wells Fargo Healthcare Conference - 16/06/10

Edwards Lifesciences to Present at the Wells Fargo Healthcare Conference - 16/06/10

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Wells Fargo Healthcare Conference at the InterContinental Hotel in Boston, Massachusetts on Wednesday, June 23, 2010.

Find out more...


AccuVein Awarded Top Prize in Prestigious Medical Product Design Competition-11/06/10

AccuVein Awarded Top Prize in Prestigious Medical Product Design Competition-11/06/10

Portable, Non-Contact Vein Finder wins Gold Award for Design Excellence

Find out more...


Cook Medical Files Pre-Market Approval Application for FDA Approval of Zilver® PTX® Drug-Eluting Stent Platform- 11/06/10

Cook Medical Files Pre-Market Approval Application for FDA Approval of Zilver® PTX® Drug-Eluting Stent Platform- 11/06/10

Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's unique polymer-free Zilver® PTX® Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), Zilver PTX is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion.

Find out more...


Boston Scientific Announces European Launch and First Implants of Platinum Chromium TAXUS® Element™ Stent System - 10.06.10

Boston Scientific Announces European Launch and First Implants of Platinum Chromium TAXUS® Element™ Stent System - 10.06.10

CE Mark approval includes specific indication for treatment of diabetic patients

Find out more...


AccuVein Awarded Top Prize in Prestigious Medical Product Design Competition - 10.06.10

AccuVein Awarded Top Prize in Prestigious Medical Product Design Competition - 10.06.10

Portable, Non-Contact Vein Finder wins Gold Award for Design Excellence

Find out more...


FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS- 10.06.10

FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS- 10.06.10
  • Committee voted in favor of approval of FTY720 (fingolimod), as treatment in relapsing remitting multiple sclerosis, affirming the drug's positive benefit/risk profile
  • FTY720, potentially first in a new class of MS therapy, represents a significant advance as an efficacious oral treatment for people with relapsing remitting MS
  • Committee recommended post marketing collection of additional safety data and evaluation of a lower dose

 

Find out more...


Results Presented from Phase IIb Clinical Study of Merck’s Investigational Insomnia Therapy MK-4305 - 09.06.10

Results Presented from Phase IIb Clinical Study of Merck’s Investigational Insomnia Therapy MK-4305 - 09.06.10

Data Reported at SLEEP 2010 24th Annual Meeting of the Associated Professional Sleep Societies

Find out more...


BD Signs Agreements to Sell Ophthalmic Systems Unit, Other Platforms - 08.06.10

BD Signs Agreements to Sell Ophthalmic Systems Unit, Other Platforms - 08.06.10

Agreements include surgical blades, critical care and extended dwell catheter product platforms

Find out more...


CryoLife Receives FDA 510(k) Clearance for CryoValve(R) SG Pulmonary Heart Valve Shelf-life Extension - 08.06.10

CryoLife Receives FDA 510(k) Clearance for CryoValve(R) SG Pulmonary Heart Valve Shelf-life Extension - 08.06.10

ATLANTA, June 8, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve(R) SG pulmonary human heart valve processed with the Company's proprietary SynerGraft(R) technology.

Find out more...


SORIN GROUP ACQUIRES GISH BIOMEDICAL- 08.06.10

SORIN GROUP ACQUIRES GISH BIOMEDICAL- 08.06.10

Sorin Group, (Reuters Code: SORN.MI), a global company and a leader in the treatment of cardiovascular diseases, announced today that it has acquired Gish Biomedical from Ventizz Capital Partners, a private equity group focused on technology-oriented companies.

Find out more...


John G. McHutchison, MD, to Join Gilead Sciences as Senior Vice President, Liver Disease Therapeutics- 08/06/10

John G. McHutchison, MD, to Join Gilead Sciences as Senior Vice President, Liver Disease Therapeutics- 08/06/10

 Dr. McHutchison will also join Gilead's Executive Committee.

Find out more...


Technology Brings New Hope for People With Heart Failure - 07.06.10

Technology Brings New Hope for People With Heart Failure - 07.06.10

An acute cardiomyopathy sends a new mom to the brink of death. A Redskins fan with heart failure is sidelined by his illness. A heart condition keeps a hunting enthusiast from the activity he loves most.

Find out more...


BD Launches World's Smallest Pen Needle - 07.06.10

BD Launches World's Smallest Pen Needle  - 07.06.10

BD Ultra-Fine™ Nano 4 mm x 32 G Pen Needle Offers More Comfortable Injection, Helping Patients Adhere to Diabetes Therapy
 

Find out more...


Court Allows Cook Patent Infringement Suit Versus Endologix to Move Forward - 07.06.10

Court Allows Cook Patent Infringement Suit Versus Endologix to Move Forward - 07.06.10

Bloomington, IN, June 7, 2010 — The United States District Court, Southern District of Indiana, has ruled in favor of Cook Incorporated in its decision to lift the stay on Cook's patent infringement case against Endologix, Inc. (Nasdaq: ELGX). With this ruling, the case, filed by Cook on October 6, 2009, will now proceed.

Find out more...


Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer live longer without their disease worsening- 06.06.10

Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer live longer without their disease worsening- 06.06.10

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.  

Find out more...


Study at ASCO shows Novartis drug Afinitor® first to shrink SEGA brain tumors in children and adults with tuberous sclerosis - 05.06.10

Study at ASCO shows Novartis drug Afinitor® first to shrink SEGA brain tumors in children and adults with tuberous sclerosis - 05.06.10
  • Phase II study shows meaningful reduction in brain tumor size in 75% of patients with subependymal giant cell astrocytomas (SEGAs) from baseline to six months
  • SEGAs are benign brain tumors associated with tuberous sclerosis (TS) that primarily affect children and adolescents and can cause severe brain swellingNo patient developed new tumors or needed brain surgery, the only current treatment option for patients with SEGAs that are growing
  • Novartis submitted file to FDA based on this study of 28 patients and is enrolling the EXIST Phase III trials to further study everolimus in patients with TS

Find out more...


Authorisation Application To European Union For Cardiovascular Drug Axanum - 04.06.10

Authorisation Application To European Union For Cardiovascular Drug Axanum - 04.06.10

Find out more...


Gilead Sciences and ADAP Crisis Task Force Announce New Initiatives to Support AIDS Drug Assistance Programs (ADAPs) - 04.06.10

Gilead Sciences and ADAP Crisis Task Force Announce New Initiatives to Support AIDS Drug Assistance Programs (ADAPs) - 04.06.10
  • Lower Prices for Gilead HIV Medicines under ADAPs, Effective July 1, 2010
  • New Pricing Frozen to ADAPs through 2013
  • Key Enhancements Made to Gilead HIV Patient Assistance and Co-Pay Programs

Find out more...


CryoLife Strengthens BioGlue(R) Surgical Adhesive Portfolio with Patent Purchase - 04.06.10

CryoLife Strengthens BioGlue(R) Surgical Adhesive Portfolio with Patent Purchase - 04.06.10

CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company whose products include BioGlue Surgical Adhesive, announced today that it has completed the purchase of U.S. patent # 6,329,337.

Find out more...


Merck Announces Launch of Pioneering Collaborative Cancer Trials Network at 2010 American Society of Clinical Oncology Meeting - 03.06.10

Merck Announces Launch of Pioneering Collaborative Cancer Trials Network at 2010 American Society of Clinical Oncology Meeting - 03.06.10

Merck strengthens its commitment to oncology

Find out more...


BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus - 02.06.10

BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus - 02.06.10

Bench-top System Offers Walkaway Automation and Improves Lab Efficiency

Find out more...


Baxter Names New President of Renal Business and New Chief Financial Officer - 01.06.10

Baxter Names New President of Renal Business and New Chief Financial Officer - 01.06.10

DEERFIELD, Ill., June 1, 2010 -- Baxter International Inc. (NYSE:BAX) announced today two executive changes.  Robert M. Davis, has been appointed corporate vice president and president of Baxter's Renal business, filling a role vacated by Bruce H. McGillivray, who is retiring after 30 years of service to the company.

Find out more...


New Study Shows Metallic Stent Gives Long-Term Relief from Ureteral Blockage - 01.06.10

New Study Shows Metallic Stent Gives Long-Term Relief from Ureteral Blockage - 01.06.10

A 29-month clinical study1 demonstrated the long-term success of Cook Medical's Resonance® Metallic Ureteral Stent in providing drainage for patients with both benign and malignant upper urinary tract obstructions, according to results presented today at the 2010 Annual Meeting of the American Urological Association (AUA).

Find out more...


Advisory Committee Briefing Materials for Motavizumab NDA Available on US FDA Web Site- 28/05/10

Advisory Committee Briefing Materials for Motavizumab NDA Available on US FDA Web Site- 28/05/10

The US Food and Drug Administration (FDA) today posted briefing materials in advance of 2 June 2010 Antiviral Drugs Advisory Committee to discuss the approval of motavizumab for the prevention of serious respiratory syncytial virus (RSV) disease in high-risk infants.

Find out more...


Roche’s Newly Launched Next-Generation DNA Sequencer Opens Innovation in Genomic Research to Broad Scientific Community - 27.05.10

Roche’s Newly Launched Next-Generation DNA Sequencer Opens Innovation in Genomic Research to Broad Scientific Community - 27.05.10

GS Junior Benchtop System expected to accelerate research in life sciences and human health

Find out more...


Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint- 27/05/10

Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint- 27/05/10

Novartis announced today that patupilone (EPO906) did not show a significant overall survival advantage in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy The comparator arm in the trial was Doxil®/Caelyx® (pegylated liposomal doxorubicin).

Find out more...


Boston Scientific Begins Platinum Plus Trial for Promus® Element™ Stent System - 26.05.10

Boston Scientific Begins Platinum Plus Trial for Promus® Element™ Stent System - 26.05.10

Randomized study of nearly 3,000 patients to evaluate Company's third-generation drug-eluting stent technology

Find out more...


Edwards Lifesciences Announces Receipt of CE Mark for Pulmonic Transcatheter Valve - 26/05/10

Edwards Lifesciences Announces Receipt of CE Mark for Pulmonic Transcatheter Valve  - 26/05/10

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced the receipt of CE Mark for the Edwards SAPIEN pulmonic transcatheter heart valve. The valve is designed to be an alternative to surgical valve replacement for patients suffering from congenital heart disease of the pulmonic valve and leverages the company's transcatheter valve technology, which has been used in more than 5,000 cases around the world.

Find out more...


Martin Mackay to Lead AstraZeneca's Research and Development Organisation- 26/05/10

Martin Mackay to Lead AstraZeneca's Research and Development Organisation- 26/05/10

AstraZeneca today announced the appointment of Martin Mackay to the newly-created position of President of R&D. Martin will lead the company’s research and development organisation and will have overall accountability for delivering new products – small molecules and biologics – from AstraZeneca’s pipeline. He will start his new role on 1 July 2010 and will be based at the company’s headquarters in London.

Find out more...


Abbott Announces European Launch of TREK™ Catheter System, Representing an Advancement in Balloon Technology- 26/05/10

Abbott Announces European Launch of TREK™ Catheter System, Representing an Advancement in Balloon Technology- 26/05/10

Abbott (NYSE: ABT) today announced the European approval and launch of its TREK™ Coronary Dilatation Catheter for the treatment of coronary artery disease. The TREK system represents a new approach to balloon catheter design, and provides physicians with a high-performing option for treating challenging lesions and difficult-to-reach blockages. Abbott received CE Mark for the TREK system earlier this year.

Find out more...


Merck Announces Third Quarter 2010 Dividends- 26/05/10

Merck Announces Third Quarter 2010 Dividends- 26/05/10

At their meeting today, the Board of Directors of Merck & Co., Inc. declared a quarterly dividend of $0.38 per share on the company’s common stock for the third quarter of 2010. Payment will be made on July 8, 2010 to common stockholders of record at the close of business on June 15, 2010.

Find out more...


Edwards SAPIEN Transcatheter Heart Valve Shows Positive One-Year Outcomes in Rigorous Post-Market Study - 25/05/10

Edwards SAPIEN Transcatheter Heart Valve Shows Positive One-Year Outcomes in Rigorous Post-Market Study - 25/05/10

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Martyn Thomas, M.D., reported that the Edwards SAPIEN transcatheter heart valve demonstrated promising one-year mortality rates for high-risk patients, many of whom were too sick to undergo traditional open-heart surgery. The 1,038-patient SOURCE Registry is the largest reported experience in the world with one-year adjudicated data on consecutive patients treated with transcatheter heart valves with either a transfemoral or transapical approach.
 

Find out more...


Abbott's Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results- 25/05/10

Abbott's Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results- 25/05/10

New Six-Month Data on Abbott's Bioresorbable Vascular Scaffold Reinforces Its Potential to Be the Next Revolution in Interventional Cardiology

Find out more...


Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy-25/05/10

Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy-25/05/10

US Food and Drug Administration (FDA) extends priority review period by three months to September 2010, in line with previously announced expectations

Find out more...


Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes- 22/05/10

Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes- 22/05/10

Study shows around 40% of ranibizumab patients substantially improved vision by 10 letters or more on an eye-chart, compared to 16% with laser therapy alone[1]
Ranibizumab, given alone or with laser, provided average vision gain of six letters sustained over a year compared to 0.8 letters with laser therapy alone[1]
Diabetic macular edema (DME) with visual impairment affects 1-3% of people with diabetes worldwide[2] with potentially disabling impact on patients' lives
New data support current submission for EU approval of ranibizumab for visual impairment caused by DME

Find out more...


BD Celebrates Opening of Manufacturing Facility in Mebane, North Carolina - 20/05/10

BD Celebrates Opening of Manufacturing Facility in Mebane, North Carolina - 20/05/10

BD (Becton, Dickinson and Company), a leading global medical technology company, today celebrated the grand opening of its newest BD Diagnostics production facility in Mebane, North Carolina. To date, BD has invested $14 million in the 101,000-square-foot facility in Alamance County, which will employ 75 associates, creating 30 new jobs for the County. The new facility provides added manufacturing capacity for diagnostic products that support BD’s Women’s Health and Cancer strategy.

Find out more...